Volume : 13, Issue : 08, August – 2026
Title:
UPDATES ON SAFETY AND EFFECTIVENESS OF SEMAGLUTIDE IN WEIGHT LOSS AMONG OBESE PATIENTS WITHOUT DIABETES: A SYSTEMATIC REVIEW
Authors :
Dr. Nada Zainalabden Tawfeeq, Khalil Ibrahim Bo grain, Amal Abdullah Alhayek, Fatimah Mossa Alahmad, Hawra Mohammed Bu hulayqah, Zainab Abdulrzzak Aldajani, Sakainh Waleed Abdraboh, Yara Waleed Alsaeed, Sara Abdullah Alali, Hawraa Ayesh Al-Ibrahim, Maryam Abdulmonem Bukhamsin
Abstract :
Objectives: to conduct a critical assessment and provide an overview of the most recent research on Semaglutide’s safety and efficacy in helping obese individuals without diabetes lose weight.
Methods: 1323 pertinent papers were found after a comprehensive search across four databases. The search produced 511 publications after eliminating duplicates using Rayyan QCRI and screening for relevancy. Of these, 115 full-text articles were examined, and 5 of them satisfied the requirements for evidence synthesis.
Results: Less than half of the 27,620 patients in the 5 trials we examined were female (8143, 29.5%). Additionally, emaglutide has been shown to significantly lower cardiovascular event rates in obese patients, which may indicate possible cost savings associated with obesity-related health issues.
The drug has also emerged as an effective add-on treatment for post-bariatric patients, ensuring prolonged benefits of up to one year regardless of demographic influences. Semaglutide further increases exercise capacity and induces weight loss and improved physical function in heart failure patients compared to placebo. Additionally, it helps non-diabetic individuals at risk lose a significant amount of weight, which lowers the risk of serious cardiovascular events.
Conclusion: Semaglutide was found to be safe and effective for the management of obesity; its benefits transcend mere weight loss to an improvement in cardiovascular outcomes and the maintenance of weight loss post-surgery. The uniform efficacy across such a diverse range of patients makes this drug a potential key in the management of obesity and its related chronic diseases. Future studies will be required to look at deficiencies in the current body of literature, long-term safety, and optimization of dosing for maximum benefit. Clinically, Semaglutide may not only improve health outcomes for an individual but also reduce the healthcare burden of obesity and cardiovascular diseases.
Keywords: Ozempic; Semaglutide; obesity; weight loss; Systematic review.
Cite This Article:
Please cite this article in press Dr. Nada Zainalabden Tawfeeq et al., Updates on safety and effectiveness of semaglutide in weight loss among obese patients without diabetes: a systematic review,, Indo Am. J. P. Sci, 2026; 13(08).
REFERENCES:
1. WHO Consultation on Obesity (1999: Geneva, Switzerland) & World Health Organization. (2000).
2. Canadian Agency for Drugs and Technologies in Health . CADTH common drug review: pharmacoeconomic review report: semaglutide (Ozempic) (Novo Nordisk Canada Inc.). 2019. Accessed Nov 2, 2024.
3. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061.
4. Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23.
5. Gao X, Hua X, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:935823. Published 2022 Sep 14.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
7. Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.
8. Fornes A, Huff J, Pritchard RI, Godfrey M. Once-Weekly Semaglutide for Weight Management: A Clinical Review. J Pharm Technol. 2022 Aug;38(4):239-246. doi: 10.1177/87551225221092681. Epub 2022 May 13.
9. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011 Oct 18;343.
10. Bergink AP, Uitterlinden AG, Van Leeuwen JP, Buurman CJ., Hofman A, Verhaar JAN, et al. Vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee: the Rotterdam study. J Clin Rheumatol 2009;15(5):230–7.
11. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Prisma-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015 Dec;4:1-9.
12. Wong ND, Karthikeyan H, Fan W. US population eligibility and estimated impact of semaglutide treatment on obesity prevalence and cardiovascular disease events. Cardiovascular Drugs and Therapy. 2023 Aug 14:1-0.
13. Lautenbach A, Kantowski T, Wagner J, Mann O, Stoll F, Aberle J. Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post‐bariatric treatment failure. Clinical Obesity. 2023 Oct;13(5):e12593.
14. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. 2023 Sep 21;389(12):1069-84.
15. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023 Dec 14;389(24):2221-32.
16. Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, Colhoun HM, Cercato C, Dicker D, Horn DB, Hovingh GK. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine. 2024 May 13:1-9.
17. Deng Y, Park A, Zhu L, Xie W, Pan CQ. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Therapeutic advances in chronic disease. 2022 Jul;13:20406223221108064.
18. Alanazi M, Alshahrani JA, Aljaberi AS, Alqahtani BA, Muammer M. Effect of Semaglutide in Individuals With Obesity or Overweight Without Diabetes. Cureus. 2024 Aug 27;16(8):e67889.
19. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Diabetes Obes Metab. 2017;19:1242–1251.
20. Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol 2020; 8: 377–391.Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol 2020; 8: 377–391.
21. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 2022; 57: 101351.
22. Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring) 2023;31:703–15.
23. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020;5:133429.
24. Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther 2021;38:2821–39.